Axitinib has been evaluated across early- to late-phase clinical trials as monotherapy as well as in combination with immunotherapies such as pembrolizumab or nivolumab. These protocols target advanced solid tumors, renal cell carcinoma (including metastatic, unresectable, and TFE3-rearranged subtypes), breast cancer, and non-small cell lung carcinoma across actively recruiting, active not recruiting, completed, and terminated statuses. Numerous clinical trials are supported by diverse sponsors, including the National Cancer Institute, academic medical centers, and pharmaceutical companies such as Pfizer and Incyte Corporation.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07383441 | RECRUITING | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
SWOG Cancer Research Network |
2026-06-05 | PHASE3 |
| NCT06364631 | RECRUITING | Metastatic Kidney Cancer; Metastatic Kidney Carcinoma |
Gustave Roussy, Cancer Campus, Grand Paris |
2024-04-12 | PHASE3 |
| NCT06726421 | RECRUITING | Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic |
Sun Yat-sen University |
2024-09-18 | PHASE3 |
| NCT07516132 | RECRUITING | Neovascular Age-Related Macular Degeneration (nAMD) |
Ocular Therapeutix, Inc. |
2026-04-27 | PHASE3 |
| NCT07277972 | NOT_YET_RECRUITING | RCC, Renal Cell Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2026-02-15 | PHASE2 |
| NCT07469683 | RECRUITING | Clear Cell Renal Cell Carcinoma; Neoplasms; Malignant Neoplasms; Malignant Neoplasm of Kidney, Except Renal Pelvis |
Yonsei University |
2026-03 | PHASE2 |
| NCT04341181 | RECRUITING | Cancer; Tumors; Neoplasms; Neoplasia |
Ulrik Lassen |
2020-08-24 | PHASE2 |
| NCT05327686 | RECRUITING | Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma |
NRG Oncology |
2023-02-01 | PHASE2 |
| NCT07500831 | NOT_YET_RECRUITING | Carcinoma, Renal Cell; Metastatic Renal Cell Carcinoma; Advanced Renal Cell Carcinoma |
Qilu Hospital of Shandong University |
2026-04 | |
| NCT07630363 | NOT_YET_RECRUITING | Advanced Renal Cell Carcinoma (RCC); PTC; Atorvastatin; Targeted Therapy Combined With Immunotherapy |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2026-05-14 | PHASE1; PHASE2 |
| NCT04693468 | RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm |
M.D. Anderson Cancer Center |
2020-12-01 | PHASE1 |
| NCT05738694 | RECRUITING | Renal Cell Carcinoma; Neoadjuvant |
ZHOU FANGJIAN |
2023-04-19 | PHASE3 |
| NCT06424626 | ENROLLING_BY_INVITATION | Melanoma; Mucosal Melanoma; Metastatic Melanoma |
Peking University Cancer Hospital & Institute |
2024-05-28 | PHASE1 |
| NCT07776717 | NOT_YET_RECRUITING | Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma |
Fudan University |
2026-08-20 | PHASE2 |
| NCT07744932 | RECRUITING | Oligometastatic Clear Cell Renal Cell Carcinoma |
Hebei Medical University Fourth Hospital |
2026-08-15 | PHASE2 |
| NCT07227415 | RECRUITING | Carcinoma, Renal Cell; Advanced Renal Cell Carcinoma; Renal Cancer; Renal Neoplasm; Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma; Carcinoma, Renal Cell Metastasis; Advanced or Metastatic Renal Cell Carcinoma; Carcinoma, Renal Cell, Advanced; Metastatic Renal Cell Cancer; Metastatic Renal Cell Carcinoma ( mRCC); Metastatic/Advanced Renal Cell Carcinoma |
Pfizer |
2026-02-10 | PHASE1; PHASE2 |
| NCT07123090 | RECRUITING | Metastatic Renal Cell Carcinoma; Metastatic Renal Cancer; Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma; Kidney Cancer; Translocation Renal Cell Carcinoma |
Stephanie Berg |
2025-11-24 | PHASE2 |
| NCT02925234 | RECRUITING | Cancer; Tumors; Neoplasm; Neoplasia |
The Netherlands Cancer Institute |
2016-08 | PHASE2 |
| NCT06962787 | RECRUITING | Renal Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2025-07-28 | PHASE2 |
| NCT05384496 | RECRUITING | Mucosal Melanoma |
Memorial Sloan Kettering Cancer Center |
2022-05-17 | PHASE2 |
| NCT07235085 | RECRUITING | Non-Proliferative Diabetic Retinopathy |
Ocular Therapeutix, Inc. |
2025-11-17 | PHASE3 |
| NCT06889649 | RECRUITING | Radiation Therapy; Targeted Therapy; Immunotherapy; Renal Cancer Metastatic |
Peking University First Hospital |
2019-01-01 | PHASE2 |
| NCT07159191 | NOT_YET_RECRUITING | Advanced Renal Cell Carcinoma (aRCC) |
Peking Union Medical College Hospital |
2025-09-01 | PHASE2 |
| NCT06495918 | ACTIVE_NOT_RECRUITING | Neovascular Age-related Macular Degeneration |
Ocular Therapeutix, Inc. |
2024-11-27 | PHASE3 |
| NCT03839498 | ACTIVE_NOT_RECRUITING | Pheochromocytoma; Paraganglioma |
Columbia University |
2019-01-22 | PHASE2 |
| NCT05363631 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma Metastatic |
Mohammed Milhem |
2022-09-19 | PHASE1; PHASE2 |
| NCT03297606 | RECRUITING | Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors |
Canadian Cancer Trials Group |
2018-03-23 | PHASE2 |
| NCT05059522 | ACTIVE_NOT_RECRUITING | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors |
Pfizer |
2021-09-29 | PHASE3 |
| NCT03092856 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Cancer; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer |
University of Southern California |
2017-07-19 | PHASE2 |
| NCT05768464 | RECRUITING | Non-clear Renal Cell Carcinoma |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2023-02-01 | PHASE2 |
| NCT03172754 | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma |
Fox Chase Cancer Center |
2017-06-12 | PHASE1; PHASE2 |
| NCT05969496 | RECRUITING | Renal Cancer; Kidney Cancer; Renal Cell Carcinoma; Inferior Vena Cava Thrombosis |
University of Colorado, Denver |
2023-12-04 | PHASE2 |
| NCT05805501 | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma |
Hoffmann-La Roche |
2023-04-21 | PHASE2 |
| NCT06860386 | SUSPENDED | Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma |
H. Lee Moffitt Cancer Center and Research Institute |
2025-02-25 | PHASE2 |
| NCT05176288 | WITHDRAWN | Advanced Clear Cell Renal Cell Carcinoma |
Bradley A. McGregor, MD |
2024-05-31 | PHASE2 |
| NCT04996823 | ACTIVE_NOT_RECRUITING | Melanoma |
H. Lee Moffitt Cancer Center and Research Institute |
2021-08-04 | PHASE2 |
| NCT07172386 | RECRUITING | Renal Cell Carcinoma (RCC) |
Tianjin Medical University Second Hospital |
2025-07-31 | PHASE2 |
| NCT06690697 | RECRUITING | Clear Cell Renal Cell Carcinoma |
Fudan University |
2024-06-01 | PHASE2 |
| NCT05263609 | WITHDRAWN | Renal Cell Cancer |
University of Oklahoma |
2022-06 | PHASE2 |
| NCT05017012 | COMPLETED | Advanced or Metastatic Solid Tumors |
Merck Sharp & Dohme LLC |
2021-09-21 | PHASE1 |
| NCT06223958 | ACTIVE_NOT_RECRUITING | Neovascular Age-Related Macular Degeneration |
Ocular Therapeutix, Inc. |
2024-01-29 | PHASE3 |
| NCT05817903 | RECRUITING | Metastatic Renal Cell Carcinoma |
Consorzio Oncotech |
2023-04-18 | PHASE2 |
| NCT05808608 | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma; First-line Treatment; Non Clear Cell Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma |
Hao Zeng |
2023-11-17 | PHASE1; PHASE2 |
| NCT06485908 | NOT_YET_RECRUITING | Medulloblastoma; Ependymoma |
Assistance Publique Hopitaux De Marseille |
2024-10 | PHASE1; PHASE2 |
| NCT03438708 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma |
University of California, San Diego |
2018-03-05 | PHASE2 |
| NCT06279403 | NOT_YET_RECRUITING | Clear-cell Metastatic Renal Cell Carcinoma; Immune Checkpoint Inhibitors; Cytoreductive Nephrectomy |
RenJi Hospital |
2024-03-01 | PHASE2 |
| NCT01409200 | COMPLETED | Metastatic Malignant Neoplasm in Lymph Node; Prostate Ductal Adenocarcinoma; Stage III Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7 |
M.D. Anderson Cancer Center |
2012-03-26 | PHASE2 |
| NCT06211114 | RECRUITING | Collecting Duct Carcinoma |
Peking University Cancer Hospital & Institute |
2024-02-09 | PHASE2 |
| NCT05256472 | COMPLETED | Renal Cell Carcinoma; First-line Treatment |
Akeso |
2023-07-06 | PHASE2 |
| NCT04522323 | ACTIVE_NOT_RECRUITING | Advanced Renal Cell Carcinoma |
MedImmune LLC |
2020-08-05 | PHASE1 |
| NCT06161558 | WITHDRAWN | Neoplasms |
National Cancer Institute (NCI) |
2025-07-15 | PHASE1 |
| NCT06020352 | UNKNOWN | NSCLC |
Shanghai Pulmonary Hospital, Shanghai, China |
2023-08-25 | PHASE2; PHASE3 |
| NCT05949632 | TERMINATED | Advanced Solid Tumors |
Incyte Corporation |
2024-04-16 | PHASE1; PHASE2 |
| NCT04337970 | COMPLETED | Kidney Cancer; Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma |
Memorial Sloan Kettering Cancer Center |
2020-04-06 | PHASE1; PHASE2 |
| NCT04370509 | TERMINATED | Metastatic Clear Cell Renal Cell Carcinoma; Recurrent Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Clear Cell Renal Cell Carcinoma |
University of California, San Francisco |
2021-02-09 | PHASE2 |
| NCT04197219 | WITHDRAWN | Recurrent Endometrial Cancer |
Case Comprehensive Cancer Center |
2021-02-01 | PHASE2 |
| NCT05522231 | ACTIVE_NOT_RECRUITING | Advanced Renal Cell Carcinoma |
Hutchmed |
2022-10-27 | PHASE2; PHASE3 |
| NCT05420220 | COMPLETED | Advanced Non-small Cell Lung Cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2022-07-26 | PHASE2 |
| NCT04458259 | TERMINATED | Neoplasm Metastasis |
Pfizer |
2020-09-24 | PHASE1 |
| NCT05904730 | COMPLETED | Breast Cancer; Ovarian Cancer; Breast Neoplasms; Ovarian Neoplasms; BRCA Mutation; HER2-positive Breast Cancer; HER2-negative Breast Cancer; HER-2 Protein Overexpression |
Lynkcell Europe |
2023-07-11 | PHASE1 |
| NCT04562441 | COMPLETED | Recurrent or Metastatic NPC |
Chinese University of Hong Kong |
2021-05-06 | PHASE2 |
| NCT05096390 | UNKNOWN | Papillary Renal Cell Carcinoma Type 2 |
Centre Leon Berard |
2022-06-01 | PHASE2 |
| NCT03595124 | ACTIVE_NOT_RECRUITING | Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; TFE3-Rearranged Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma |
National Cancer Institute (NCI) |
2019-01-08 | PHASE2 |
| NCT04640545 | COMPLETED | Advanced Melanoma |
Nanjing Leads Biolabs Co.,Ltd |
2020-05-12 | PHASE1 |
| NCT05097599 | TERMINATED | Cancer; Advanced Solid Tumor |
Strata Oncology |
2022-04-29 | PHASE2 |
| NCT06161558 | Not yet recruiting | Neoplasms |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2024-05-15 | Phase 1 |
| NCT04873895 | TERMINATED | Colorectal Neoplasms Malignant |
Abramson Cancer Center at Penn Medicine |
2022-01-24 | PHASE1 |
| NCT04493203 | COMPLETED | Advanced Melanoma; Unresectable Melanoma |
Yana Najjar |
2020-12-18 | PHASE2 |
| NCT04394975 | COMPLETED | Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 |
Shanghai Junshi Bioscience Co., Ltd. |
2020-08-20 | PHASE3 |
| NCT05949632 | Recruiting | Advanced Solid Tumors |
Incyte Corporation |
2024-04-16 | Phase 1|Phase 2 |
| NCT03826589 | COMPLETED | Cervical Cancer |
The University of Hong Kong |
2019-06-01 | |
| NCT04540705 | COMPLETED | Renal Cell Carcinoma |
Bristol-Myers Squibb |
2020-09-11 | PHASE1 |
| NCT03013946 | TERMINATED | Renal Cell Carcinoma, Metastatic; Renal Cell Cancer, Recurrent |
AIO-Studien-gGmbH |
2017-01-18 | PHASE3 |
| NCT04010071 | UNKNOWN | Hepatobiliary Neoplasm; Liver Neoplasm; Biliary Tract Neoplasms |
Peking Union Medical College Hospital |
2020-05-01 | PHASE2 |
| NCT05695417 | UNKNOWN | Non-proliferative Diabetic Retinopathy |
Ocular Therapeutix, Inc. |
2023-01-15 | PHASE1 |
| NCT01744249 | COMPLETED | Neuroendocrine Tumors; Advanced Cancer |
Grupo Espanol de Tumores Neuroendocrinos |
2011-11 | PHASE2; PHASE3 |
| NCT05816642 | UNKNOWN | Metastatic Renal Cell Carcinoma |
RenJi Hospital |
2022-08-01 | |
| NCT05969496 | Recruiting | Renal Cancer|Kidney Cancer|Renal Cell Carcinoma|Inferior Vena Cava Thrombosis |
University of Colorado Denver|Cancer League of Colorado |
2023-12-04 | Phase 2 |
| NCT05172440 | UNKNOWN | Neoadjuvant Therapy |
Hongqian Guo |
2021-12-09 | PHASE2 |
| NCT02912572 | ACTIVE_NOT_RECRUITING | Metastatic Endometrial Cancer |
Dana-Farber Cancer Institute |
2016-11-14 | PHASE2 |
| NCT05070221 | UNKNOWN | Melanoma Stage IV |
Peking University Cancer Hospital & Institute |
2021-10-01 | PHASE1 |
| NCT04459663 | UNKNOWN | Non-small Cell Lung Cancer |
Li Zhang, MD |
2020-08-31 | PHASE2 |
| NCT04698213 | UNKNOWN | Renal Carcinoma Metastatic |
Consorzio Oncotech |
2020-10-07 | PHASE2 |
| NCT02684006 | COMPLETED | Renal Cell Cancer |
Pfizer |
2016-03-23 | PHASE3 |
| NCT02535533 | COMPLETED | Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) |
Mohammed Milhem |
2016-01 | PHASE1; PHASE2 |
| NCT00828919 | COMPLETED | Solid Tumors |
Pfizer |
2003-03-07 | |
| NCT05904730 | Enrolling by invitation | Breast Cancer|Ovarian Cancer|Breast Neoplasms|Ovarian Neoplasms|BRCA Mutation|HER2-positive Breast Cancer|HER2-negative Breast Cancer|HER-2 Protein Overexpression |
Lynkcell Europe |
2023-07-11 | Phase 1 |
| NCT04764487 | UNKNOWN | Renal Cell Carcinoma Metastatic |
Weprom |
2021-06-07 | PHASE3 |
| NCT04585815 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Pfizer |
2020-11-10 | PHASE1; PHASE2 |
| NCT05817903 | Recruiting | Metastatic Renal Cell Carcinoma |
Consorzio Oncotech|Pfizer |
2023-04-18 | Phase 2 |
| NCT03990571 | COMPLETED | Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma |
M.D. Anderson Cancer Center |
2019-07-22 | PHASE2 |
| NCT04118855 | COMPLETED | Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma |
RenJi Hospital |
2020-03-01 | PHASE2 |
| NCT03472560 | TERMINATED | Non-Small Cell Lung Cancer; Urothelial Cancer |
Pfizer |
2018-05-02 | PHASE2 |
| NCT04989699 | COMPLETED | Neovascular Age-Related Macular Degeneration |
Ocular Therapeutix, Inc. |
2021-07-28 | PHASE1 |
| NCT03341845 | UNKNOWN | Renal Cell Carcinoma |
The Netherlands Cancer Institute |
2018-03-28 | PHASE2 |
| NCT05249569 | TERMINATED | Hepatocellular Carcinoma |
University of Texas Southwestern Medical Center |
2022-11-04 | PHASE2 |
| NCT03386929 | TERMINATED | Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB |
Worldwide Innovative Network Association |
2017-11-29 | PHASE1; PHASE2 |
| NCT04995016 | UNKNOWN | Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma |
Tianjin Medical University Second Hospital |
2021-08-20 | PHASE2 |
| NCT04958473 | UNKNOWN | Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma |
Tianjin Medical University Second Hospital |
2021-08-01 | PHASE2 |
| NCT04180995 | UNKNOWN | Mucosal Melanoma |
Peking University Cancer Hospital & Institute |
2019-08-06 | PHASE2 |
| NCT03941795 | UNKNOWN | Advanced Mucosal Melanoma |
Peking University Cancer Hospital & Institute |
2019-11-11 | PHASE2 |
| NCT05263609 | Withdrawn | Renal Cell Cancer |
University of Oklahoma|Merck Sharp & Dohme LLC|Pfizer |
2022-06 | Phase 2 |
| NCT02667886 | COMPLETED | Clear Cell Renal Cell Carcinoma |
X4 Pharmaceuticals |
2016-04-27 | PHASE1; PHASE2 |
| NCT02638428 | UNKNOWN | Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Relapsed Pediatric AML; Refractory Pediatric AML |
Samsung Medical Center |
2015-12 | PHASE2 |
| NCT04385654 | UNKNOWN | Neoadjuvant Therapy; Advanced Cancer; Metastatic Kidney Cancer |
West China Hospital |
2020-06 | PHASE2 |
| NCT03481842 | WITHDRAWN | Endometriosis; Endometriosis Ovary; Endometriosis Externa; Endometriosis, Rectum |
BioGene Pharmaceutical Ltd. |
2021-10-10 | PHASE1; PHASE2 |
| NCT04258956 | COMPLETED | Gastrointestinal Stromal Tumors |
Maria Sklodowska-Curie National Research Institute of Oncology |
2019-04-30 | PHASE2 |
| NCT01263769 | COMPLETED | Kidney Cancer |
M.D. Anderson Cancer Center |
2011-02 | PHASE2 |
| NCT03736330 | UNKNOWN | Renal Cancer Metastatic |
Sun Yat-sen University |
2018-09-08 | PHASE2 |
| NCT02639182 | COMPLETED | Metastatic Renal Cell Carcinoma |
Astellas Pharma Global Development, Inc. |
2016-05-03 | PHASE2 |
| NCT02762513 | COMPLETED | Squamous Cell Carcinoma of the Head and Neck |
University of Michigan Rogel Cancer Center |
2016-08-30 | PHASE2 |
| NCT03494816 | COMPLETED | Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Non-metastatic Renal Cell Carcinoma |
Scottish Clinical Trials Research Unit |
2017-12-15 | PHASE2 |
| NCT03086174 | UNKNOWN | Kidney Cancer Stage Iv; Advanced Melanoma |
Shanghai Junshi Bioscience Co., Ltd. |
2017-03-31 | PHASE1 |
| NCT03592199 | UNKNOWN | Clear Cell Renal Cell Carcinoma |
Instituto do Cancer do Estado de São Paulo |
2017-12-11 | PHASE2 |
| NCT02782403 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia (CML); Blast Phase Chronic Myelogenous Leukemia (CML); Chronic Phase Phase Chronic Myelogenous Leukemia (CML); Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML) |
M.D. Anderson Cancer Center |
2017-03-20 | PHASE1 |
| NCT03289533 | COMPLETED | Carcinoma, Hepatocellular |
Pfizer |
2017-09-08 | PHASE1 |
| NCT02579811 | COMPLETED | Metastatic Renal Cell Cancer |
Case Comprehensive Cancer Center |
2015-12-30 | PHASE2 |
| NCT02489695 | COMPLETED | Papillary Renal Cell Carcinoma |
Centre Leon Berard |
2015-10 | PHASE2 |
| NCT04355156 | COMPLETED | Colorectal Cancer |
Imperial College London |
2012-09-17 | PHASE2 |
| NCT02129647 | COMPLETED | Neurofibromatosis Type 2; Vestibular Schwannomas |
NYU Langone Health |
2014-04 | PHASE2 |
| NCT03291314 | COMPLETED | Recurrent Glioblastoma (WHO-Grade IV Glioma) |
Universitair Ziekenhuis Brussel |
2017-05-03 | PHASE2 |
| NCT01806064 | TERMINATED | Renal Cell Carcinoma |
Tracon Pharmaceuticals Inc. |
2013-03-08 | PHASE1; PHASE2 |
| NCT02814461 | COMPLETED | Advanced Hepatocellular Carcinoma (HCC) |
Shin Kong Wu Ho-Su Memorial Hospital |
2015-11 | PHASE1 |
| NCT02853331 | COMPLETED | Renal Cell Carcinoma |
Merck Sharp & Dohme LLC |
2016-09-16 | PHASE3 |
| NCT02857712 | COMPLETED | Salivary Gland Cancers |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2014-12 | PHASE2 |
| NCT01562197 | COMPLETED | Glioblastoma Multiforme |
Bart Neyns |
2014-04 | PHASE2 |
| NCT03275558 | WITHDRAWN | Recurrent Glioblastoma; Gliosarcoma; Anaplastic Gliomas |
Center Trials & Treatment |
2018-07-17 | PHASE1 |
| NCT01352728 | COMPLETED | Hepatocellular Carcinoma |
Chinese University of Hong Kong |
2011-05-18 | PHASE2 |
| NCT02700568 | COMPLETED | Carcinoma, Renal Cell; Clear Cell Renal Cell Carcinoma |
Kidney Cancer Research Bureau |
2016-01 | PHASE2 |
| NCT02636725 | COMPLETED | Alveolar Soft Part Sarcoma; Soft Tissue Sarcomas |
Jonathan Trent, MD, PhD |
2016-04-19 | PHASE2 |
| NCT02493751 | COMPLETED | Renal Cell Cancer |
Pfizer |
2015-10-26 | PHASE1 |
| NCT01334112 | COMPLETED | Hepatocellular Carcinoma |
University Health Network, Toronto |
2011-01 | PHASE2 |
| NCT02859012 | COMPLETED | Recurrent ACC, metastaticACC, Unreaectable ACC |
Seoul National University Hospital |
2016-09 | PHASE2 |
| NCT02164838 | COMPLETED | Refractory or Recurrent Solid Tumors, Excluding CNS Tumors |
Children's Oncology Group |
2014-09 | PHASE1 |
| NCT01599754 | TERMINATED | Clear Cell Renal Carcinoma |
SFJ Pharma Ltd. II |
2012-04 | PHASE3 |
| NCT02261207 | COMPLETED | Solitary Fibrous Tumor |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2014-11 | PHASE2 |
| NCT02560012 | TERMINATED | Carcinoma, Renal Cell |
The University of Texas Health Science Center, Houston |
2016-01-04 | PHASE2 |
| NCT01727336 | TERMINATED | Advanced Renal Cell Carcinoma |
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA |
2012-12 | PHASE2 |
| NCT02133742 | COMPLETED | Renal Cell Carcinoma |
Pfizer |
2014-09-16 | PHASE1 |
| NCT01693822 | COMPLETED | Clear-cell Metastatic Renal Cell Carcinoma |
Institute of Cancer Research, United Kingdom |
2012-10 | PHASE2 |
| NCT01999972 | COMPLETED | Advanced Solid Tumors |
Pfizer |
2014-02-26 | PHASE1 |
| NCT01435122 | COMPLETED | Carcinoid Tumor |
H. Lee Moffitt Cancer Center and Research Institute |
2011-10-25 | PHASE2 |
| NCT01249547 | COMPLETED | Recurrent or Metastatic NPC |
Chinese University of Hong Kong |
2010-12 | PHASE2 |
| NCT01321437 | COMPLETED | Melanoma; Malignant Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma |
University of California, Irvine |
2011-12 | PHASE2 |
| NCT01558661 | COMPLETED | Adenoid Cystic Carcinoma |
Memorial Sloan Kettering Cancer Center |
2012-03 | PHASE2 |
| NCT01140737 | COMPLETED | Soft Tissue Sarcoma |
Sheffield Teaching Hospitals NHS Foundation Trust |
2010-08-31 | PHASE2 |
| NCT01273662 | COMPLETED | Hepatocellular Carcinoma |
National Taiwan University Hospital |
2011-04 | PHASE2 |
| NCT01649180 | TERMINATED | Renal Cell Carcinoma |
PrECOG, LLC. |
2012-07 | PHASE2 |
| NCT02597322 | COMPLETED | cT2a N0NxM0 Renal Tumor |
Assistance Publique - Hôpitaux de Paris |
2012-02 | PHASE2 |
| NCT01483638 | TERMINATED | Colorectal Carcinoma |
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
2012-02 | PHASE2 |
| NCT01533948 | TERMINATED | Extraocular Extension Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IIIA Intraocular Melanoma; Stage IIIA Melanoma; Stage IIIB Intraocular Melanoma; Stage IIIB Melanoma; Stage IIIC Intraocular Melanoma; Stage IIIC Melanoma; Stage IV Intraocular Melanoma; Stage IV Melanoma |
Roswell Park Cancer Institute |
2012-01 | PHASE2 |
| NCT01490866 | COMPLETED | Colorectal Cancer |
SCRI Development Innovations, LLC |
2012-01 | PHASE2 |
| NCT01967576 | COMPLETED | Pheochromocytoma; Paraganglioma |
National Cancer Institute (NCI) |
2013-10-19 | PHASE2 |
| NCT01798446 | COMPLETED | Renal Cell Carcinoma; Nonclear Cell; Temsirolimus Resistance |
Seoul National University Hospital |
2013-02 | PHASE2 |
| NCT01469546 | COMPLETED | Head and Neck Squamous Cell Carcinoma |
University of Michigan Rogel Cancer Center |
2012-01 | PHASE2 |
| NCT01540526 | COMPLETED | Solid Malignancies; Metastatic Castrate-resistant Prostate Cancer |
University of Wisconsin, Madison |
2012-03 | PHASE1 |
| NCT01441414 | TERMINATED | Metastatic Renal Cell Carcinoma |
Pfizer |
2011-11-21 | PHASE2 |
| NCT01210495 | COMPLETED | Hepatocellular Carcinoma |
Pfizer |
2010-12-06 | PHASE2 |
| NCT01529138 | COMPLETED | Cancer |
Emory University |
2011-10 | PHASE1 |
| NCT01441388 | WITHDRAWN | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular |
Pfizer |
2011-12 | PHASE1 |
| NCT01385059 | COMPLETED | Stage III Prostate Cancer; Stage IV Prostate Cancer |
City of Hope Medical Center |
2011-10-28 | PHASE2 |
| NCT01174238 | COMPLETED | Melanoma |
Adil Daud |
2010-07 | PHASE2 |
| NCT01334073 | COMPLETED | Malignant Advanced Solid Tumors; Carcinoma, Renal Cell |
University Hospital, Bordeaux |
2011-03 | PHASE1 |
| NCT00859118 | COMPLETED | Neoplasms |
University of Wisconsin, Madison |
2009-02 | PHASE1 |
| NCT01486251 | COMPLETED | Colorectal Carcinoma |
Gustave Roussy, Cancer Campus, Grand Paris |
2011-09 | |
| NCT01255137 | COMPLETED | Adrenal Cortex Neoplasms |
National Cancer Institute (NCI) |
2010-09 | PHASE2 |
| NCT01211275 | COMPLETED | Malignant Pleural Mesothelioma |
The Netherlands Cancer Institute |
2009-05-22 | PHASE1; PHASE2 |
| NCT00835978 | COMPLETED | Carcinoma, Renal Cell |
Pfizer |
2009-08 | PHASE2 |
| NCT01508117 | TERMINATED | Glioblastoma Multiforme |
University of Cincinnati |
2011-08 | PHASE2 |
| NCT00920816 | COMPLETED | Kidney Neoplasms |
Pfizer |
2009-08-25 | PHASE3 |
| NCT00460603 | COMPLETED | Colorectal Neoplasms |
Pfizer |
2006-01 | PHASE1; PHASE2 |
| NCT00600821 | COMPLETED | Non-Small-Cell Lung Carcinoma; Adenocarcinoma |
Pfizer |
2008-04 | PHASE2 |
| NCT00768755 | COMPLETED | Carcinoma, Non-Small Cell Lung |
Pfizer |
2009-01 | PHASE1; PHASE2 |
| NCT00615056 | COMPLETED | Colorectal Neoplasms |
Pfizer |
2008-03 | PHASE2 |
| NCT00678392 | COMPLETED | Kidney Neoplasms |
Pfizer |
2008-09-03 | PHASE3 |
| NCT00726752 | COMPLETED | Neoplasms |
Pfizer |
2008-07 | PHASE1 |
| NCT00842244 | COMPLETED | Stomach Neoplasms; Advanced Gastric Cancer |
Pfizer |
2009-04 | PHASE1 |
| NCT00447005 | COMPLETED | Carcinoma |
Pfizer |
2007-02 | PHASE1 |
| NCT00919204 | COMPLETED | Healthy Volunteers |
Pfizer |
2009-08 | PHASE1 |
| NCT00454649 | COMPLETED | Neoplasms |
Pfizer |
2005-12 | PHASE1 |
| NCT00282048 | COMPLETED | Kidney Neoplasms; Carcinoma, Renal Cell |
Pfizer |
2006-03 | PHASE2 |
| NCT00094107 | COMPLETED | Melanoma; Skin Neoplasms |
Pfizer |
2004-12 | PHASE2 |
| NCT00094094 | COMPLETED | Lung Neoplasms; Carcinoma, Non-small Cell Lung |
Pfizer |
2005-02 | PHASE2 |
| NCT00076024 | COMPLETED | Breast Neoplasms |
Pfizer |
2004-02 | PHASE1; PHASE2 |
| NCT00071006 | COMPLETED | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome |
Pfizer |
2003-09 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-06-11)
Check the
Axitinib (AG-013736)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Axitinib (AG-013736) Mechanism of Action: VEGFR Inhibition in Tumor Endothelial Cells Research
- Axitinib (AG-013736): Selectivity & Specificity
- Axitinib (AG-013736) Working Concentration | Cell Culture | Treatment
- Axitinib (AG-013736) Solubility in DMSO
- Axitinib (AG-013736) Stock Solution
- Axitinib (AG-013736) Storage
- Axitinib (AG-013736) Stability
- Axitinib (AG-013736) Combination Database
- Axitinib (AG-013736) Molecular Weight
- Axitinib (AG-013736) SMILES
- Axitinib (AG-013736) CAS Number
- Axitinib (AG-013736) Chemical Structure (2D and 3D)
- Axitinib (AG-013736) IC50 for Cell-based and Cell-free Assays
- Axitinib (AG-013736) APExBIO (A8370)? Try a better option.
- Axitinib (AG-013736) Cayman (13813)? Try a better option.
- Axitinib (AG-013736) MedChemExpress (HY-10065)? Try a better option.
- Axitinib (AG-013736) Sigma (AMBH2D6ED301)? Try a better option.
- Axitinib (AG-013736) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.